Last €86.08 EUR
Change Today -0.05 / -0.06%
Volume 13.3K
BIM On Other Exchanges
Symbol
Exchange
BIM is not on other exchanges.
As of 3:51 AM 12/29/14 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Open
€85.90
Previous Close
€86.13
Day High
€86.10
Day Low
€85.70
52 Week High
12/1/14 - €87.46
52 Week Low
01/14/14 - €73.59
Market Cap
3.4B
Average Volume 10 Days
27.4K
EPS TTM
€3.46
Shares Outstanding
39.5M
EX-Date
06/3/14
P/E TM
24.9x
Dividend
€1.00
Dividend Yield
1.16%
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was formerly known as B-D Mérieux and changed its name to bioMérieux SA. The company was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,535 Employees
Last Reported Date: 09/5/14
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €544.9K
Compensation as of Fiscal Year 2013.

biomerieux (BIM) Key Developments

bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections

bioMérieux and Illumina announced that they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period. The first application will be an NGS epidemiological solution offered by service labs for genotyping disease agents. The high resolution of NGS combined with bioMerieux's knowledge in microbiology will provide easily accessible and highly accurate information to communities and hospitals to track, prevent, contain and stop the spread of disease agents. The solution will combine Illumina's MiSeq(R) sequencing system with a jointly developed pathogen genome database based on bioMérieux's culture collection. This collection, which contains over 80,000 references, constitutes libraries of bacterial strains in the world, and will contribute to creating a database of unprecedented scope with information about virulence and microbial resistance characteristics. The service will deliver a standardized report with a genomic profile of the infectious agents, with sequence-level accuracy and depth of information. The ultimate goal of the Illumina-bioMérieux epidemiology solution will be to enable public health and hospital microbiology laboratories to contain an epidemic, avoid transmission of infectious agents, and improve hospital practices where needed. Those facing a suspected epidemic or health crisis will be able to send the relevant isolates to a designated laboratory equipped with an Illumina sequencing system. The genetic sequences will be sent via a secure cloud platform to be analyzed, using the database and software developed by bioMérieux, which will also generate a customized report for the customer. The precise results will be presented seamlessly, in an easily understandable graphical format identifying the infectious agent as well as the sequence-based genetic variations that would assist in understanding its transmission.

bioMérieux SA Presents at HSBC Healthcare Day 2014, Nov-12-2014

bioMérieux SA Presents at HSBC Healthcare Day 2014, Nov-12-2014 . Venue: Hilton, Frankfurt, Germany.

bioMérieux SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

bioMérieux SA reported earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported sales of EUR 412.0 million compared with EUR 389.9 for the same period last year. For the nine months, the company reported sales of EUR 1,193 million compared with EUR 1,144 for the same period last year. At September 30, 2014, net debt stood at EUR 277 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €86.08 EUR -0.05

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $37.41 USD -0.07
Bio-Rad Laboratories Inc $120.87 USD +0.55
Hologic Inc $26.93 USD +0.04
QIAGEN NV €19.27 EUR +0.206
Siemens Ltd 871.20 INR +16.40
View Industry Companies
 

Industry Analysis

BIM

Industry Average

Valuation BIM Industry Range
Price/Earnings 22.1x
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow 22.1x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit www.biomerieux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.